Replies to post #87582 on Biotech Values

[mcbio]

Re: ACH-1625 vs. Telaprevir

Scratch my previous post because there’s another variable that renders the comparison in question all but meaningless: the proportion of patients who were treatment-naïve vs treatment-experienced.

Yes, good point. That does further complicate things. I don't believe ACHN formally disclosed if the HCV-infected patients in the ACH-1625 Phase 1b trial were treatment-naive or treatment-experienced or some combination thereof.